Preclinical testing of neuroprotective neurotrophic factors in a model of chronic motor neuron degeneration.
Many neurotrophic factors have been shown to enhance survival of embryonic motor neurons or affect their response to injury. Few studies have investigated the potential effects of neurotrophic factors on more mature motor neurons that might be relevant for neurodegenerative diseases. Using organotypic spinal cord cultures from postnatal rats, we have demonstrated that insulin-like growth factor-I (IGF-I) and glial-derived neurotrophic factor (GDNF) significantly increase choline acetyltransferase (ChAT) activity, but brain-derived neurotrophic factor (BDNF), neurotrophin-4 (NT-4/5), and neurotrophin-3 (NT-3) do not. Surprisingly, ciliary neurotrophic factor (CNTF) actually reduces ChAT activity compared to age-matched control cultures. Neurotrophic factors have also been shown to alter the sensitivity of some neurons to glutamate neurotoxicity, a postulated mechanism of injury in the neurodegenerative disease, amyotrophic lateral sclerosis (ALS). Incubation of organotypic spinal cord cultures in the presence of the glutamate transport inhibitor threo-hydroxyaspartate (THA) reproducibly causes death of motor neurons which is glutamate-mediated. In this model of motor neuron degeneration, IGF-I, GDNF, and NT-4/5 are potently neuroprotective, but BDNF, CNTF, and NT-3 are not. The organotypic glutamate toxicity model appears to be the best preclinical predictor to date of success in human clinical trials in ALS.
Corse
A M
AM
Department of Neurology, Johns Hopkins University School of Medicine Meyer 5-119, 600 North Wolfe Street, Baltimore, Maryland, 21287-7519, USA. acorse@welchllink.welch.jhu.edu
Bilak
M M
MM
Bilak
S R
SR
Lehar
M
M
Rothstein
J D
JD
Kuncl
R W
RW
D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000494:pharmacology; D002470:Cell Survival / Q000187:drug effects; D020934:Ciliary Neurotrophic Factor / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D051100:Glial Cell Line-Derived Neurotrophic Factor; D006131:Growth Inhibitors / Q000494:pharmacology; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines / Q000494:pharmacology; D008959:Models, Neurological; D016472:Motor Neuron Disease / Q000473:pathology* / Q000503:physiopathology; D009046:Motor Neurons / Q000166:cytology / Q000187:drug effects* / Q000473:pathology; D009410:Nerve Degeneration; D009414:Nerve Growth Factors / Q000494:pharmacology* / Q000502:physiology; D009419:Nerve Tissue Proteins / Q000494:pharmacology; D018696:Neuroprotective Agents / Q000494:pharmacology*; D020933:Neurotrophin 3 / Q000494:pharmacology; D009924:Organ Culture Techniques; D051381:Rats; D013116:Spinal Cord / Q000166:cytology / Q000187:drug effects* / Q000473:pathology
D019208:Brain-Derived Neurotrophic Factor; D020934:Ciliary Neurotrophic Factor; C495039:GDNF protein, human; C495041:Gdnf protein, rat; D051100:Glial Cell Line-Derived Neurotrophic Factor; D006131:Growth Inhibitors; D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D020933:Neurotrophin 3; D016222:Fibroblast Growth Factor 2; D007334:Insulin-Like Growth Factor I; C073922:neurotrophin 4